Objective To observe the effect of fresh orange peel flavor inhalation on the improvement of gastrointestinal reactions such as nausea and vomiting in tumor patients during chemotherapy. Methods Ninety-one inpatients undergoing chemotherapy with PF and TP regimens between May 2012 and September 2013 were included in this study. The patients were randomly divided into orange group (n=45) and control group (n=46). Patients in the control group received conventional care, while those in the orange group were treated with fresh orange peel flavor inhalation during chemotherapy. We observed the effect of orange peel flavor inhalation on such gastrointestinal reactions as nausea and vomiting in tumor patients during chemotherapy. Results All the patients completed each cycle of chemotherapy. At the fifth day during chemotherapy, compared with the control group, the incidence rates of grade Ⅲ-Ⅳ gastrointestinal reactions (nausea and vomiting) in the orange group were significantly lower (P=0.023). At the fourth day, when gastrointestinal reactions were the most significant, the food intake of patients in the orange group was significantly higher than that in the control group (P=0.012). During chemotherapy, the addition rate of antiemetic drugs in the orange group was significantly lower than that in the control group (P=0.038). In the orange group, 80.0% of the patients had good self-feeling after orange peel flavor inhalation. Conclusions The study results have shown that fresh orange peel flavor inhalation can effectively improve the gastrointestinal reactions (such as nausea and vomiting), appetite, and degree of comfort in tumor patients during chemotherapy, and reduce the use of antiemetic drugs. This study is of great significance to guide the future research on how to reduce the discomfort of on-chemotherapy patients and provide more comfortable care.
Background Mortality and morbidity of acute myocardial infarction remains high. Intravenous magnesium started early after the onset of myocardial infarction is a promising adjunctive treatment that may limit infarct size, prevent serious arrhythmias, and reduce mortality. Several earlier trials and meta-analyses demonstrated a mortality rate reduction with magnesium treatment, but one mega trial found no benefit. Objective To examine the effect of intravenous magnesium versus control on early mortality and morbidity, stratified by time since onset of symptoms (lt;6 hours, 6+ hours), use of thrombolysis (used, not used), dose of magnesium used (lt;75 mmol, 75+ mmol). Search strategy We search the Cochrane controlled trial register (CCTR) of Cochrane Library, Medline and Embase. We also search Chinese Biomedical Disk (CBM disk) to identify the Chinese trials. Each database will be searched from its starting date to the first-half year of 2002. Selection criteria All randomized controlled trials that compared intravenous magnesium with placebo in the presence or absence of fibrolytic therapy in addition to routine treatment are eligible if they reported mortality and clinical events within 35 days of onset, regardless of language. Methods of review A data abstraction form will be specifically developed to extract information from the eligible articles. The quality assessment of RCT will be focused on method of treatment assignment, blinding of participants and investigators, control of selection bias after treatment assignment. The selection of studies, data extraction and assessment of methodological quality will be performed independently by two reviewers. Disagreements will be resolved through discussion, when necessary, in consultation with a third reviewer. Publication bias, heterogeneity and sensitivity analysis will be performed. The odds ratio (OR) will be used to pooling the effect if appropriate.
Objective To access the feasibility, effectiveness and safety of transcatheter closure of ventricular septal defects(VSD) in 17patients. Methods Seventeen patients, aged 4 23 years, were selected by transthoracic echocardiography. The location of VSD was perimembranous in 16 patients and was muscular in 1 patient. And 1 patient with aneurysm formation. All cases had no severe pulmonary hypertension or right to left shunt. Membranous VSD underwent transcatheter closure with Amplatzer membranous VSD occluder or membranous VSD occluder made in China. Muscular VSD was closed by Amplatzer patent ductus arteriosus occluder. Results The VSD diameter ranged from 2.3 10.5 mm(5.75±2.10 mm). The device diameter ranged from 412 mm (7.12±1.67 mm). After application of the prosthesis there was no residual shunt in all patients. One patient developed grade I atrioventricular block and complete right bundle branch block. Two patients developed right bundle branch block after 3 4 days. No other compli...更多cations were observed in 1 12 months follow up. Conclusion The transcatheter closure of VSD appears to be a safe and effective method.
The burst strength is one of the most important characteristics for nonwovens. The strength of three kinds of the nonwoven were detected under four testing radius, including the wood spunlace nonwoven, the Spunbond-Meltblown-Spunbond (SMS) nonwoven and the melt nonwoven. The precise results of the SMS and the melt nonwoven could be received by removing the influence of the elastic membrane and the single-peak fitting. The influence of the testing radius to the strength results was also studied, and the semiempirical formula (q0=k/r3) was deduced using the elastic mechanics theory and testing data.
Objective To explore and compare the diagnostic value of blood pressure, brain natriuretic peptide (BNP), pulmonary artery systolic pressure (PASP) in evaluating right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (APE). Methods A retrospective study was conducted on 84 APE patients who were diagnosed by computed tomographic pulmonary angiography. The patients were divided into a RVD group and a non-RVD group by echocardiography. Eighteen clinical and auxiliary examination variables were used as the research factors and RVD as the related factor. The relationship between these research factors and RVD were evaluated by logistic regression model, the diagnostic value of BNP and PASP to predict RVD was analyzed by receiver-operating characteristic (ROC) curve analysis. Results The patients with RVD had more rapid heart rate, higher diastolic blood pressure, higher mean arterial pressure, higher incidence of BNP>100 pg/ml and higher incidence of PASP>40 mm Hg (allP<0 05="" upon="" logistic="" regression="" model="" bnp="">100 pg/ml (OR=4.904, 95%CI 1.431–16.806, P=0.011) and PASP>40 mm Hg (OR=6.415, 95%CI 1.509–27.261, P=0.012) were independent predictors of RVD. The areas under the ROC curve to predict RVD were 0.823 (95%CI 0.729–0.917) for BNP, and 0.798 (95%CI 0.700–0.896) for PASP. Conclusions Blood pressure related parameters can not serve as a predictor of RVD. Combined monitoring of BNP level and PASP is helpful for accurate prediction of RVD in patients with APE.
ObjectiveTo collect and analyze the clinical data and quality of life of hemophilic children, understand the present condition of these patients in Sichuan Province, and analyze related influencing factors. MethodWe retrospectively analyzed the clinical data of hemophilic children treated in our hospital from January 1, 2008 to May 30, 2015. ResultsThere were 92 child patients from Sichuan Province with a median age of 9.6 years old (ranging from 3.6 to 18.0). There were 87 cases (94.6%) of hemophilia A and 5 (5.4%) of hemophilia B; the number of light cases was 4 (4.3%), of moderate cases was 67 (72.8%), and of severe cases was 21 (22.9%); eighteen (19.6) of the patients had family history. First bleeding episode occurred at a median age of 11 months (0-48 months). Mild bleeding occurred in 23 cases (25.0%), moderate bleeding in 31 cases (33.7%), and severe bleeding in 38 cases (41.3%). First bleeding site was mainly the mucous membrane of the skin, followed by the joint muscles. Fist joint bleeding occurred at a median age of 18 months (2-107 months). Forty-six patients (59.0%) had severe joint damage during the course of the disease. Intracranial hemorrhage occurred in 4 patients (4.3%), among whom 3 were cured and discharged from the hospital, and 1 had neurological sequelae. Median diagnostic age was 12 months (0-120 months). Sixty-two (67.4%) were diagnosed in a short period of time, 9 (9.8%) in a mediate period of time, and 21 (22.8%) in a long period of time. Forty (43.5%) of the patients had been given sufficient coagulation factors, while all the others had not received sufficient replacement therapy. Fifty-six (60.9%) children had received prophylactic treatment. First prophylaxis was administrated at a median age of 36 months (1-199 months), but 27 (48.2%) discontinued. The median score of the 29 retreated Disease Burden Scale was 22.7±11.6 (4-43), and among them, 11 (37.9%) could not care for themselves. Twenty-three participated in the assessment of social activity ability, among whom, 2 did not attend school, and 6 could not take part in the assessment because of school learning. Correlation analysis showed that there was no significant relationship between diagnostic timing and family history (P=0.795) or between diagnostic timing and areas they came from (P=0.495). However, significant association was found between diagnostic timing and the severity of first bleeding (r=0.392, P=0.035). Disease burden of family was significantly correlated with the number of target joints (r=0.370, P=0.048), and was not closely related with area, severity of bleeding, frequency of hemorrhage, medical insurance, or physical and social activities. ConclusionsThe general diagnosis and treatment condition of child hemophilia in Sichuan is relatively under-developed with a high prevalence of joint damage, poor quality of life, and high disease burden to the family. Improvement in the care of hemophilia children is urgently needed.